MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
about
Potential approaches to the treatment of Ewing's sarcomamTOR: An attractive therapeutic target for osteosarcoma?TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.Increased Incidence of Mitochondrial Cytochrome C Oxidase 1 Gene Mutations in Patients with Primary Ovarian Insufficiency.Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.Targeting protein kinases to reverse multidrug resistance in sarcoma.PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathwaysMLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies.Dual abrogation of MNK and mTOR: a novel therapeutic approach for the treatment of aggressive cancers.The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Integrin-α10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice.Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression.Group Spike-and-Slab Lasso Generalized Linear Models for Disease Prediction and Associated Genes Detection by Incorporating Pathway Information.New targets and therapies for gastrointestinal stromal tumors.Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies.Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128.
P2860
Q28072744-E2485D76-46BE-44F3-B90E-1108A5CC7F2BQ28078490-15059518-AE21-47A7-9DCB-8D298084B4A8Q33442621-53A9D7C9-C3F6-4A78-8966-3B6D471E51C1Q35725793-B0E84B2A-12B8-4D06-992C-794520977FD1Q35910232-45BF7928-3A5D-47C1-A615-A02818A11DECQ36527950-760532A7-7731-4CE7-9B4D-102B6968143CQ36878777-63F4DFBD-7601-4671-92DD-AF108D103DC6Q37688200-F6E087E5-1ACE-4641-8553-516BBA7390B9Q38379348-8FA8A710-3D8C-4AEB-8FB7-0623E284F66DQ38637354-A253D6F1-F24C-4A2D-84A3-690048ABFA79Q38705818-6BC171E6-C5AA-4424-8E53-1489DB1CF9ABQ38819110-BE34EE3A-B7EC-4E76-ADAE-5DE587B0C219Q41133627-695CF4B4-5598-42D2-A92D-DD3E1C1B4472Q41636388-52497047-3B32-43C8-8FC6-0C4BA487C02DQ44126452-CB153DC6-5800-47AB-A32A-57DFBDFE478EQ45870005-38A9F5E0-2B4A-40BD-AE49-DF51AC1A1DA2Q47116845-3D45DDEC-243E-41A3-A54E-4C01947E6BE4Q47232136-4D6D26AE-9444-4DC2-8DD7-40181FC29ED6Q47311024-7CE26D9D-A755-41DB-8C04-6F5C3E30D6E8Q47432725-C7FC02C9-1EA5-493E-811B-51B42CA17CCDQ49367042-08CB17B2-2EB5-478B-BB1F-B9D4D5C22309Q49484270-BCCFFB55-076E-44B8-862B-B6ED0296A69AQ52092512-EE9D1759-B1D7-4AE2-ADBE-2C784DE401A6Q55381339-C2EA6F37-1E6F-4F6C-8C3E-1960A1EB265D
P2860
MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@ast
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@en
type
label
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@ast
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@en
prefLabel
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@ast
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@en
P2093
P2860
P1476
MLN0128, an ATP-competitive mT ...... bone and soft-tissue sarcoma.
@en
P2093
Emily K Slotkin
Gary K Schwartz
Parag P Patwardhan
Shyamprasad D Vasudeva
William D Tap
P2860
P304
P356
10.1158/1535-7163.MCT-14-0711
P577
2014-12-17T00:00:00Z